3ROWE J, BUCK G, BURNETT A, et al, Induction therapy for adults with acute lymphoblastic leukemia.. results of more than 1 500 patients from the international ALL trial:MRC UKALLXII/ECOG E2993[J]. Blood, 2005,106 : 3760-3767.
4HUGUET F, LEGUAY T, RAFFOUX E, et al. Pediatric-inspired therapy in adults with philadelphia chromosome-negative acute lymphoblastic leukemia: the graall-2003 study[J]. J Clin Oncol, 2008,27:1-8.
5STOCK W, LA M, BEN SANFORD B, et al. What determines the outcomes for adolescents and young a- dults with acute lymphoblastic leukemia treated on cooperative group protocols? Acomparison of Chil- dren's Cancer Group and Cancer and Leukemia Group B studies[J]. Blood, 2008,112:1646-1654.
6NACHMAN J,LA M, HUNGER S,et al. Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduetion treatment:A report from the Children's oncology group[J]. J Clin Oncol,2009, 27:5189-5194.
7KANTAP, JIAN H,THOMAS D,O'BRIEN S,et al. Long-term follow-up results of hyperfractionated cy- clophosphamide vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in acute lymphoblastic leukemia [J]. Cancer, 2004, 101:2788-2801.
8WASSMANN B, PFEIFER H, GOEKBUGET N, et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) [J]. Blood, 2006,108:1469-1477.
9THOMAS D A, KANTARJIAN H M, CORTES J E, et al. Outcome after Irontline therapy with the hyper-CVAD and imatinib mesylate regimen for adults with de nov0 or minimally treated Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL)[J]. Proc Am Clin Soc Oncol, 2008,26:7019a.
10YANADA M, SUGIURA I, TAKEUCHI J, et al. Japan Adult Leukemia Study Group. Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia un- dergoing imatinib-combined chemotherapy[J]. Br J Haematol, 2008,143 : 503-510.
二级参考文献31
1Takeuchi J,Kyo T, Naito K, et al. Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSC-ALL93 study [ J ]. leukemia, 2002,16 : 1259 - 1266.
2Plasschaert SL, deBont ES, Boezen M, et al. Expression of multidrug resistance-associated proteins predicts prognosis in childhood and adult acute lymphoblastic leukemia [ J ]. Clin Cancer Res, 2005,11:8661 - 8668.
3Zhu YM,Zhao WL,Fu JF,et al. NOTCH1 mutations in T-cell acute lymphoblastic leukemia:prognostic significance and implications in muhifactorial leukemogenesis [ J ]. Clin Cancer Res,2006, 12:3043 - 3049.
8Boissel N ,Auclerc MF, Lheritier V, et al. Should adolescents with acute lymphoblastic leukemia be treated as children or young adults : comparison of the French FRALLE-93 and LALA-94 [ J ]. J Clin Oncol,2003,21:774 -780.
9Ottmann OG, Wassmann B, Pfeifer H, et al. lmatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia ( Ph + ALL) [ J ]. Cancer, 2007,109:2068 - 2076.
10Advani AS ,Jin T, Ramsingh G, et al. Time to post-remission therapy is an independent prognostic factor in adults with acute lymphoblastic leukemia[ J ]. Leuk Lymphoma ,2008 ,49 : 1560 - 1566.
